Literature DB >> 11545334

Mass psychogenic illness following tetanus-diphtheria toxoid vaccination in Jordan.

S Kharabsheh1, H Al-Otoum, J Clements, A Abbas, N Khuri-Bulos, A Belbesi, T Gaafar, N Dellepiane.   

Abstract

In September 1998, more than 800 young people in Jordan believed they had suffered from the side-effects of tetanus-diphtheria toxoid vaccine administered at school; 122 of them were admitted to hospital. For the vast majority, their symptoms did not result from the vaccine but arose from mass psychogenic illness. The role played by the media, the children's parents, and the medical profession in the escalation of this mass reaction appeared, at first sight, to be unusual and even unique to the circumstances in Jordan at the time. A review of the literature showed, however, that this mass reaction was similar in many ways to previous outbreaks, even though the underlying causes varied. There are about 200 published accounts of mass responses to situations involving suspected poisoning or other events. Because such mass reactions are relatively rare and the triggers so diverse, individuals faced with responding to them are unlikely to have prior experience in how to handle them and are unlikely to take bold steps to prevent their escalation. Indeed they may be unaware that such events have been recorded before. The lessons learned from this incident in Jordan may help other immunization programme managers to handle crisis situations elsewhere.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11545334      PMCID: PMC2566491     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  11 in total

1.  Misled and confused? Telling the public about MMR vaccine safety. Measles, mumps, and rubella.

Authors:  C J Clements; S Ratzan
Journal:  J Med Ethics       Date:  2003-02       Impact factor: 2.903

2.  Mass sociogenic illness.

Authors:  Erica Weir
Journal:  CMAJ       Date:  2005-01-04       Impact factor: 8.262

3.  Experimental induction of psychogenic illness in the context of a medical event and media exposure.

Authors:  Joan E Broderick; Evonne Kaplan-Liss; Elizabeth Bass
Journal:  Am J Disaster Med       Date:  2011 May-Jun

4.  Considerations on immunization anxiety-related reactions in clusters.

Authors:  Ricardo Palacios
Journal:  Colomb Med (Cali)       Date:  2014-09-30

Review 5.  Where is the mind in COVID-19 causality?

Authors:  Jean-Luc Mommaerts
Journal:  Brain Behav Immun Health       Date:  2022-03-04

Review 6.  Mass psychogenic illness after vaccination.

Authors:  C John Clements
Journal:  Drug Saf       Date:  2003       Impact factor: 5.228

Review 7.  Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa.

Authors:  Monique Berlier; Rodrigue Barry; John Shadid; Coimbra Sirica; Alison Brunier; Hayatee Hasan; Enricke Bouma
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

8.  Outbreak of mass sociogenic illness in a school feeding program in northwest Bangladesh, 2010.

Authors:  Farhana Haque; Subodh Kumar Kundu; Md Saiful Islam; S M Murshid Hasan; Asma Khatun; Partha Sarathi Gope; Zahid Hayat Mahmud; A S M Alamgir; M Sirajul Islam; Mahmudur Rahman; Stephen P Luby
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

9.  Mass Psychogenic Illness: Demography and Symptom Profile of an Episode.

Authors:  Binoy Krishna Tarafder; Mohammad Ashik Imran Khan; Md Tanvir Islam; Sheikh Abdullah Al Mahmud; Md Humayun Kabir Sarker; Imtiaz Faruq; Md Titu Miah; S M Yasir Arafat
Journal:  Psychiatry J       Date:  2016-05-16

Review 10.  Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.

Authors:  Mamoudou H Djingarey; Fabien V K Diomandé; Rodrigue Barry; Denis Kandolo; Florence Shirehwa; Clement Lingani; Ryan T Novak; Carol Tevi-Benissan; William Perea; Marie-Pierre Preziosi; F Marc LaForce
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.